A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Sponsor
Hoffmann-La Roche
Study ID
NCT01670045
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Tocilizumab in accordance with the licensed label recommendation.

Study Details

This multi-center observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the licensed label will be followed for 6 months.

Key Dates

Start date
Mar 31, 2012
Status verified
Sep 2016
Primary completion
Jun 30, 2014
Completion
Jun 30, 2014

Study Design

Enrollment
43 participants (actual)

Arms

  • Arm: Rheumatoid Arthritis Participants
    Participants with moderate to severe rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score based on 28 Joint Count (DAS28) who were on tocilizumab treatment within 8 weeks prior to start of study will receive tocilizumab in accordance with the licensed label recommendations, and will be observed for 6 months. The study is designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication is required.

Primary Outcome Measure

Percentage of Participants Who Remained on Tocilizumab Treatment at 6 Months After Treatment Initiation [ Time Frame: Month 6 ]

Related Studies